As insulin resistance is a major pathophysiologic abnormality of T2D, insulin-sensitizing agents that could restore insulin resistance and control hyperglycemia in T2D patient, has been interested in therapeutic approach [6]. The gene discussed is INS; the disease is Insulin resistance.